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Abstract
Background. Monocyte subsets are involved in atherosclerotic vascular disease and its thromboembolic 
complications. Moreover, the role of monocytes has been suggested in the pathogenesis of venous throm-
boembolism (VTE).
Objectives. We hypothesized that pro-inflammatory non-classical and intermediate monocytes are in-
creased in the first months following VTE.
Material and methods. We enrolled 70 patients aged 18–65 years (mean age 41.6 ±11.6) with the first-
ever provoked (n = 32; 45.7%) or unprovoked (n = 38; 54.28%) VTE episode, and 46 healthy controls. 
The exclusion criteria were: acute infection, cancer, autoimmune disorders, previous myocardial infarction 
(MI), or stroke. Monocyte subsets were assessed 12 (8.5–21.5) months after VTE using flow cytometry and 
were defined as classical (CD14++CD16–), intermediate (CD14++CD16+) and non-classical (CD14+CD16++).
Results. Patients with VTE had higher intermediate and non-classical monocyte counts compared to the con-
trol group (16.8 ±9.3 vs 10.4 ±4.0 cells/μL, and 64.1 ±25.2 vs 44.1 ±19.2 cells/μL, respectively, both 
p < 0.001). Increased non-classical monocyte counts were observed in patients who experienced a VTE 
incident within 12 months prior to enrollment (71.5 ±27.4 vs 56.03 ±20.6 cells/μL; p = 0.01) and those 
with unprovoked VTE (70.2 ±4.1 vs 58.8 ±4.3 cells/μL; p = 0.06). There were no differences in monocyte 
subsets related to the current anticoagulation.
Conclusions. Our data has shown for the first time that VTE is associated with an increased number of non-
classical and intermediate monocytes, which may indicate the involvement of monocyte-related mechanisms 
in the pathophysiology of this disease.
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Introduction
Venous thromboembolism (VTE), including deep 
vein thrombosis (DVT) and pulmonary embolism (PE), 
is a common disease associated with significant mortality 
and substantial healthcare costs. Venous thromboembo-
lism occurs in approx. 1 to 2 per 1,000 person per year, 
and the overall VTE incidence is similar to that of strokes.1 
Idiopathic VTE events represent 25–40%. The morbid-
ity  rises dramatically after about 45  years of  age and 
is slightly higher for men than for older women.1–3 Ve-
nous thromboembolism is the 3rd most common cause 
of cardiovascular death worldwide, just after myocardial 
infarction (MI) and stroke.4 
There is evidence that inflammation and thrombosis are 
closely linked, but the nature of this relationship is poorly 
understood. Increased level of C-reactive protein (CRP), 
a major marker of inflammation, has been shown to be 
associated with VTE in the general population as well 
as  DVT, in  particular in  those with post-thrombotic 
syndrome that occurs in 20–50% of the patients within 
the first 2 years since the event.5–9 In addition, acute in-
fections predispose to DVT, which also supports the role 
of inflammation in thrombosis.10,11 Levels of CRP and IL-6 
at the time of the DVT diagnosis were associated with 
thrombotic disease burden, as measured by DVT extent 
and severity of DVT symptoms and signs.12
Identification of  internal prothrombotic functions 
of cells of the innate immune system, which acts in blood 
vessels, resulted in  an  intriguing concept of  immu-
nothrombosis.13–16 Involvement of  the  immune system 
in  the  thrombosis process represents a  physiological 
mechanism, an independent line of host defense against 
microorganisms that mediates in the identification of and 
protection against pathogens by promoting microthrom-
bi in the vessels.7–9 Immunothrombosis is triggered and 
maintained by the local accumulation of innate immune 
cells, mainly monocytes and neutrophils. Dysregulation 
of immunothrombotic reactions can, therefore, contribute 
to thrombotic disorders, including DVT, in individuals 
free of infections.7 During development of DVT, activat-
ed endothelial cells adopt a proinflammatory phenotype, 
which initiates the recruitment of innate immune cells, 
particularly monocytes and neutrophils. Active participa-
tion of cells of the innate immune system in the formation 
of thrombi is a specific attribute of thrombosis, as indi-
cated by studies on mouse models of DVT.14 It has been 
demonstrated in animals that the DVT begins as a ster-
ile inflammation characterized by a massive recruitment 
of neutrophils and monocytes. The role of monocytes 
in VTE observed in human subjects is, however, unclear. 
Monocytes represent a  heterogeneous cell popula-
tion in both phenotype and function. Based on the ex-
pression of CD14 and CD16, 3 monocyte subsets can be 
differentiated: classical (CD14++CD16–), intermediate 
(CD14++CD16+) and non-classical (CD14+CD16++). CD16 
antigen is identified as FcyRIIIA and is involved in innate 
immunity, while CD14 is a coreceptor of toll-like receptor 
4 that binds lipopolysaccharide (LPS). The correct count 
of the number of individual subsets of monocytes requires 
staining and appropriate gating strategy, which includes 
a 3rd pan-monocyte marker, i.e., HLA-DR or CD86. CD16+ 
monocytes are the  main producers of  tumor necrosis 
factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6, which 
indicates that intermediate or non-classical monocytes 
or both jointly produce the largest quantities of the pro-
inflammatory cytokines.17–20 
Recently, Mukherjee et al. have shown that non-classical 
CD14+CD16++ subtype of monocytes displays inflamma-
tory characteristics and properties for antigen presenta-
tion.21 In turn, intermediate CD14++CD16+ appear to be 
transitional monocytes that display both phagocytic and 
inflammatory functions, whereas classical monocytes 
CD14++CD16– are phagocytic with low inflammatory 
attributes.21
Growing evidence suggests that proinflammatory sub-
sets of monocytes are involved in atherosclerosis and its 
thromboembolic complications. Higher numbers of pro-
inflammatory intermediate or non-classical monocytes 
have been shown in patients with a stable and unstable 
coronary artery disease (CAD).22,23 In patients with stable 
CAD, cardiovascular events can be predicted by elevated 
counts of intermediate monocytes.24 Intermediate mono-
cytes have also been shown to be positively correlated with 
peak cardiac troponin and inflammatory markers in pa-
tients with acute ST segment elevation MI that is caused 
in  the vast majority of cases by a  thrombus occluding 
a coronary artery.25 In unstable angina patients counts 
of intermediate monocytes, intermediate monocyte-plate-
let aggregates and total monocyte-platelet aggregates are 
increased, and are independent of traditional risk factors.26 
Hypercholesterolemia is also associated with an elevated 
number of non-classical monocytes, while HDL-choles-
terol showed a  negative association.27 Elevated counts 
of intermediate monocytes have also been demonstrated 
in patients during the first days after an ischemic stroke.28
Despite the fact that monocyte subpopulations have been 
assessed in various diseases and experimental studies have 
shown a causative role of monocytes in the pathogenesis 
of VTE, to our knowledge there have been no published 
studies assessing various subsets of circulating monocytes 
in patients following VTE.29,30
Methods
Patients
We  investigated 70 consecutive Caucasian patients, 
aged 18–65 years, with a history of  the  first-ever pro-
voked or unprovoked DVT alone or in combination with 
PE, referred to an outpatient clinic between October 2012 
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and June 2015. The diagnosis of DVT was established 
by a positive finding on color duplex sonography (visualiza-
tion of an intraluminal thrombus in calf, popliteal, femoral, 
or iliac veins). The diagnosis of PE was based on the pres-
ence of typical symptoms and positive results of computed 
tomography pulmonary angiography (CT). Patients with 
signs of acute infection, known cancer, chronic inflam-
matory disease, or autoimmune disorders (including an-
tiphospholipid syndrome), previous MI or stroke, serum 
creatinine ≥120 μM, liver injury, pregnancy were ineligible. 
All patients were treated with unfractionated or low-mo-
lecular-weight heparin, and then vitamin K antagonists 
(VKA) were continued for at least 3 months in patients with 
VTE triggered by transient risk factors and for 6 months 
or longer on the discretion of the treating physicians in pa-
tients with unprovoked VTE. A VTE episode was defined 
as unprovoked (idiopathic) if the patient had no history 
of cancer, surgery requiring general anesthesia, major trau-
ma, a plaster cast or hospitalization within the last month, 
or pregnancy or delivery within the last 3 months. A proxi-
mal DVT was defined as thrombosis in the popliteal veins, 
including the  trifurcation, the  femoral and iliac veins.
Forty-six consecutive healthy volunteers served as the 
control group. The  exclusion criteria were: personal 
and/or family history of cardiovascular diseases including 
VTE, MI, CAD, heart failure, stroke, and any of chronic 
diseases except for arterial hypertension, as well as age 
over 65 years. All subjects denied taking any medication 
on a long-term basis and within the previous month.
Body mass index (BMI) was calculated as weight in ki-
lograms divided by the square of height in meters. Obe-
sity was defined as a BMI of 30 kg/m2 or higher. Diabetes 
mellitus was defined as the previous diagnosis of diabetes, 
or at least 2 random fasting glucose levels of >7 mmol/L. 
Arterial hypertension was diagnosed based systolic or dia-
stolic pressure ≥140 mm Hg or ≥90 mm Hg, respectively, 
on at least 2 different occasions or the use of antihyper-
tensive treatment. Hypercholesterolaemia was diagnosed 
based on low-density lipoprotein cholesterol (LDL-C) level 
>3.0 mmol/L or previously diagnosed hypercholesterolae-
mia. The diagnosis of MI was based on the 2012 American 
Heart Association, European Society of Cardiology, Amer-
ican College of Cardiology Foundation, and World Heart 
Federation (ESC/ACCF/AHA/WHF) guidelines. Ischemic 
stroke was diagnosed according to the World Health Orga-
nization criteria. Smoking was defined as the use of at least 
1 cigarette per day. 
The Ethical Committee by Regional Medical Council 
in Kraków (No. 135/KBL/OIL/2013) approved the study and 
all the participants provided their written informed consent.
Laboratory investigations
Fasting blood samples were drawn between 8 a.m. and 
12 a.m. from an antecubital vein with minimal stasis. Se-
rum triglycerides, total cholesterol, LDL-C, high-density 
lipoprotein cholesterol (HDL-C), creatinine and glucose, 
total protein and albumin, and complete blood count were 
assayed using a biochemical analyser Cobas 6000™ (Roche 
Diagnostics GmbH, Mannheim, Germany). Fibrinogen was 
determined using the Clauss method. A high-sensitivity 
CRP (hs-CRP) was determined using immunoturbidim-
etry (Roche Diagnostics GmbH). 
A complete blood count was determined using the he-
matological analyzer Sysmex XT2000i (Sysmex Corpora-
tion, Kobe, Japan). Anti-nuclear antibodies (ANA) were 
tested using indirect fluorescent assay (IFA) in sera diluted 
at 1:160 (Euroimmun, Lübeck, Germany).
Flow cytometry
The number of monocytes was assessed in blood sam-
ples an average of 12 months after the incident of VTE. 
Whole blood samples were drawn into EDTA-K3 collec-
tion tubes and were prepared for flow cytometry within 
30 min. Briefly, 50 µL of whole blood was incubated with 
antibody mix containing 10 µL of  FITC-labeled anti-
human CD14 (B36297, Beckman Coulter, Brea, USA), 
10 µL PE-labeled anti-human CD16 (332779, BD Biosci-
ences, San Jose, USA), 10 uL PerCP-labelled anti-human 
HLA-DR (347402, BD Biosciences), 5 µL APC-labeled 
anti-human CD45 (340910, BD Biosciences) in BD Tru-
count tubes (all from BD Bioscience) for 30 min in room 
temperature in the dark. The  isotype control was run 
in parallel. Lysis of erythrocytes was performed using 
450 µL of  BD FACS Lysing Solution (BD  Bioscience) 
for 5 min. Determination of monocytes subsets were per-
formed on FACSCanto II flow cytometry (BD Bioscience) 
and analyzed by FACSDiva software v. 7.0 (BD Biosci-
ences). The following calculation has been performed: 
[(number of events in quadrant containing cell popula-
tion)/(number of events in absolute-count bead region)] 
× [(number of beads per test defined by manufacturer)/
(test volume)], to  obtain the  number of  monocytes 
per microliter.
Monocyte subpopulation identification
The  absolute number of  monocyte subpopulations 
was determined as described previously.31 Briefly, based 
on CD45-positive and SSC characteristics, monocytes were 
gated together with adjacent lymphocytes, including NK 
cells (Fig. 1A). Then, to exclude CD14-negative and HLA-
DR-negative NK cells (gate “d”), a gate “c” was defined 
including CD14-positive and HLA-DR-positive events 
(Fig. 1B). All events from gate “c” were then divided based 
on CD14 and CD16 expression into: classical monocytes 
CD14++CD16− (gate “e”) expressing high levels of CD14 but 
no CD16; intermediate monocytes CD14++CD16+ (gate “f”) 
expressing high levels of CD14 and low CD16; and non-
classical monocytes CD14+CD16++ (gate “g”) expressing 
low CD14 but high CD16 (Fig 1C).
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Statistical analysis
Assuming a standard deviation (SD) for non-classical 
monocytes of 25/μL, the study would require a sample size 
of 44 for each group to demonstrate 2-sided equality and 
to achieve a power of 0.8 and a level of significance of 0.05, 
for detecting a difference in means of this monocyte subset 
between the VTE and the control group of 15/μL.32
Categorical variables are presented as numbers and per-
centages. Continuous variables are expressed as mean ± SD 
or median and interquartile range (IQR). Normality was 
assessed by the Shapiro-Wilk test. Equality of variances 
was assessed using Levene’s test. Differences between 
groups were compared using the Student’s or the Welch’s 
t-test depending on the equality of variances for normal-
ly distributed variables. The Mann-Whitney U test was 
used for non-normally distributed continuous variables. 
Categorical variables were compared by Fisher’s exact test. 
The Pearson’s correlation coefficient was computed to mea-
sure the linear association between 2 variables. The Spear-
man’s rank correlation coefficient was calculated to mea-
sure the monotonic trend between 2 variables. Multivariate 
logistic regression models were used to adjust the results 
to age and BMI. Two-sided p-values < 0.05 were considered 
statistically significant. All calculations were done with 
JMP v. 9.0.0 (SAS Institute Inc., Cary, USA).
Results
Study participants
The characteristics of VTE patients and healthy controls 
are presented in Table 1.
Venous thromboembolism patients were slightly older 
and more overweight. The age range for the control group 
was 20–58 years and 18–64 years for the VTE patients. 
Twenty-three (32.8%) of VTE subjects had isolated DVT 
and 24 (34.3%) subjects had symptomatic PE with concomi-
tant DVT. Proximal DVT occurred in 56 (80.0%) subjects. 
More than 80% of VTE patients were treated with oral 
anticoagulants (Table 1). One patient with VTE (1.4%) had 
a history of previous MI and another one (1.4%) experi-
enced ischemic stroke in the past.
Most laboratory investigations were similar in  both 
groups. Fibrinogen was higher in  VTE patients, while 
CRP concentrations were similar (Table  1). However, 
the proportion of VTE patients with CRP >3 mg/L was 
2-fold larger compared to that found in healthy volunteers 
(Table 1). The difference remained significant after adjust-
ment for age and BMI. In VTE patients, glucose was slightly 
higher; while creatinine and albumin concentrations were 
lower (Table 1). Only the relative frequency, but not the ab-
solute count of monocytes and lymphocytes, was lower 
in VTE patients, which seems to be due to the increase 
in neutrophils without changes in the absolute blood level 
of monocytes and lymphocytes (Table 1).
Positive ANA was detected more commonly among VTE 
patients compared to the controls (Table 1).
Monocyte characteristics
Patients with VTE had higher intermediate CD14++CD16+ 
and non-classical CD14+CD16++ monocyte counts com-
pared to the control group (Table 1). These differences 
remained significant after adjustment for age and BMI. 
There were no intergroup differences in classical monocyte 
CD14++CD16– counts (Table 1). 
The  absolute number of  all 3 monocyte subsets 
in VTE patients was not associated with comorbidities, 
type of VTE or the medications used. Among the VTE 
patients, the  non-classical CD14+CD16++ monocytes 
were positively associated with age (r = 0.33; p = 0.008), 
weight (r = 0.33; p = 0.005) and BMI (r = 0.31; p = 0.009), 
while in the control group the only significant associa-
tion was found for this monocyte subpopulation and age 
Fig. 1. Gating strategy of monocytes subsets analysis by flow cytometry. Monocytes were gated as (A) CD45-positive cells vs side scatter (SSC) plot: (“a”) 
monocytes, (“b”) counting beads for determination of the absolute cell count. (B) CD14-positive cells from gate “a” were then gated (“c”) to exclude CD14-
HLA-DR-negative NK cells (“d”) and finally analyzed for CD14 and CD16 expression (C) as: classical monocytes (CD14++CD16–, “e”), intermediate monocytes 
(CD14++CD16+, “f”) and non-classical monocytes (CD14+CD16++, “g”)
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(r  =  0.39; p  =  0.01). Additionally, the  non-classical 
CD14+CD16++ monocyte counts showed positive cor-
relations with glucose (r = 0.26; p = 0.03) and albumin 
to globulin ratio (r = 0.26; p = 0.03).
Classical CD14++CD16– and intermediate CD14++CD16+ 
monocyte counts were positively associated with leuko-
cyte counts (r = 0.67 and r = 0.51, respectively, p < 0.0001 
for  both). Classical CD14++CD16– and non-classical 
CD14+CD16++ monocyte counts showed positive corre-
lations with hsCRP (r = 0.25 and r = 0.27, respectively, 
p = 0.03 for both). However, after removing of 3 outliners, 
only the trend towards correlation between non-classical 
monocytes and CRP was found (r = 0.2; p = 0.08). 
Only intermediate CD14++CD16+ monocyte counts 
were positively associated with FVIII activity (r = 0.5; 
p = 0.03). There was no correlation of these counts with 
D-dimer and ANA antibody. Interestingly, the patients 
who had a VTE incident within 12 months prior to en-
rollment (9 (6–10) months) were characterized by an in-
creased number of non-classical CD14+CD16++ mono-
cytes as compared to those who experienced a VTE event 
at an earlier, more distant time point (21 (15–29) months) 
(71.5 ±27.4 vs 56.03 ±20.6 cells/μL, p = 0.01; Fig. 2).
As shown in Fig. 3, non-classical CD14+CD16++ mono-
cyte counts tended to be higher in patients following un-
provoked VTE as compared to individuals with provoked 
VTE (70.2 ±4.1 vs 58.8 ±4.3 cells/μL; p = 0.06).
Discussion
This study shows that  a  history of  VTE, regardless 
of the type of thrombotic event and anticoagulant treat-
ment, is associated with increased counts of non-classical 
CD14+CD16++ and intermediate CD14++CD16+ monocytes. 
Table 1. Characteristics of the study participants
Parameters Control (n = 46)
VTE  
(n = 70) p-value
Age [years] 36.98 ±10.09 41.61 ±11.55 0.03
Male sex, n [%] 22 (47.83) 23 (32.86) 0.12
Body mass index [kg/m2] 24.19 ±3.78 26.82 ±5.25 0.004
Obesity, n [%] 3 (6.52) 15 (21.43) 0.04
Clinical characteristics, n [%]
Current smoking 6 (13.04) 14 (20.00) 0.25
Arterial hypertension 0 17 (24) –
Diabetes mellitus 0 5 (7.14) –
Hypercholesterolemia 20 (43) 36 (51.42) 0.31
Unprovoked VTE 0 38 (54.28) –
DVT alone 0 23 (32.85) –
PE + DVT 0 24 (34.28) –
Proximal DVT 0 56 (80.00) –
Family history of VTE 0 25 (35.71) –
Time from the last VTE 
event [months]
n.a. 12.0 (8.5–21.5) –
Laboratory parameters
Glucose [mmol/L] 4.98 ±0.55 5.38 ±0.66 0.002
Creatinine [µmol/L] 77.17 ±13.01 71.27 ±14.16 0.01
Total cholesterol [mmol/L] 4.88 ±0.86 5.13 ±0.95 0.11
HDL cholesterol [mmol/L] 1.64 ±0.32 1.60 ±0.41 0.31
LDL cholesterol [mmol/L] 3.08 ±0.83 3.31 ±0.89 0.10
Triglycerides [mmol/L] 1.13 ±0.68 1.24 ±0.79 0.62
Total protein [g/L] 74.84 ±4.41 74.49 ±4.34 0.83
Albumin [g/L] 40.80 ±2.63 39.40 ±2.80 0.007
Albumin/globulin ratio 1.21 ±0.16 1.14 ±0.17 0.01
ANA, n [%] 9 (19.57) 24 (42.11) 0.004
Blood cell variables
Red blood cells [106/µL] 4.83 ±0.46 4.76 ±0.38 0.36
Hemoglobin [g/dL] 13.70 ±1.43 13.81 ±1.33 0.66
Hematocrit [%] 40.76 ±3.59 41.21 ±3.30 0.48
Platelets [103/µL] 237 ±54 255 ±59 0.16
Leukocytes [103/µL] 5.81 ±1.29 6.53 ±1.91 0.045
Neutrophils [103/µL] 3.20 ±0.94 4.05 ±1.65 0.004
Lymphocytes [103/µL] 1.94 ±0.49 1.79 ±0.54 0.08
Monocytes [103/µL] 0.55 ±0.26 0.60 ±0.77 0.41
Eosinophils [103/µL] 0.15 ±0.09 0.14 ±0.09 0.62
Basophils [103/µL] 0.03 ±0.02 0.03 ±0.01 0.40
Neutrophils [%] 54.34 ±7.12 60.80 ±9.49 <0.001
Lymphocytes [%] 33.68 ±6.35 28.63 ±8.50 <0.001
Monocytes [%] 8.82 ±1.54 7.78 ±1.96 <0.001
Eosinophils [%] 2.53 ±1.56 2.22 ±1.34 0.36
Basophils [%] 0.43 ±0.28 0.43 ±0.24 0.70
Inflammatory markers
Fibrinogen [g/L] 2.66 ±0.57 3.24 ±0.90 <0.001
hsCRP [mg/L] 1.11 (0.70–1.98) 1.23 (0.69–2.59) 0.27
hsCRP >3 mg/L, n [%] 5 (10.87) 17 (24.29) 0.02
Parameters Control (n = 46)
VTE  
(n = 70) p-value
Monocyte subsets [103/μL]
Classical 370.48 ±113.04 363.90 ±143.71 0.43
Intermediate 10.43 ±4.01 16.79 ±9.29 <0.001
Non-classical 44.09 ±19.21 64.09 ±25.21 <0.001
Non-classical/classical 
monocytes ratio
0.14 (0.11–0.18) 0.18 (0.13–0.23) 0.003
Treatment
Vitamin K antagonists n.a. 30 (42.86) –
Rivaroxaban n.a. 24 (34.28) –
No anticoagulation n.a. 10 (14.29) –
Data is shown as mean ± standard deviation (SD) or a median 
(interquartile range (IQR)) or number (percentage). VTE – venous 
thromboembolism; DVT – deep vein thrombosis; PE – pulmonary 
embolism; HDL – high-density lipoprotein; LDL – low-density lipoprotein; 
ANA – anti-nuclear antibodies, hsCRP – high sensitivity C-reactive protein; 
n.a. – not applicable.
Table 1. Characteristics of the study participants (cont.)
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This phenomenon is more pronounced in our patients 
aged 65 years or less assessed in the first 12 months from 
the VTE event, and it is in partly driven by inflammation, 
reflected by positive correlations with elevated hsCRP.
The pattern of monocytes counts in peripheral venous 
blood observed following VTE is similar to that found 
in  patients with atherosclerotic vascular disease.25,26 
It may be speculated that the non-classical and interme-
diate monocytes are involved in the similar processes 
in  patients with VTE and those with atherosclerosis. 
The  recent data has suggested that  VTE and athero-
thrombosis share similar pathophysiological pathways 
like low-grade systemic inflammation and hypercoagula-
bility state.33 The mechanisms typical of atherosclerosis 
like platelet activation and neutrophil recruitment with 
the formation of neutrophil extracellular traps are also 
involved in the pathogenesis of DVT.34 The same coagula-
tion proteins which play a crucial role in the pathophysi-
ology of VTE are also expressed in the atherosclerotic 
arterial walls enhancing the inflammatory and immune 
processes characteristic of atherosclerosis.33 Addition-
ally, the clinical association of VTE and atherothrombo-
sis has been shown for the first time by Prandoni et al., 
who demonstrated that patients with idiopatic VTE were 
more likely to have carotid artery plaque (47%) than pa-
tients with provoked VTE (27%) or age- and sex-matched 
controls (32%).35 Further studies have reported an  in-
creased risk of acute MI and stroke among patients with 
a prior history of VTE than among those without such 
a history.36,37 Also, symptomatic cardiovascular events 
may precede the incident of VTE.33 Our findings suggest 
that monocytes might contribute to the links between 
atherosclerosis and VTE.
Molecular mechanisms underlying the current findings 
study are likely complex. Increased numbers of non-clas-
sical monocytes, which are primary producers of TNF-α 
and IL-1β, may regulate the  immune response by  en-
hancing cells proliferation, migration and receptor ex-
pression in VTE patients. Accordingly, it has been shown 
that the gene expression profile exhibited by non-classical 
monocytes showed the highest expression of TNF-α and 
the metalloprotease ADAM17 gene, which are involved 
in the processing of TNF-α from the cell surface.38 More-
over, an in vitro study demonstrated that only non-clas-
sical CD14+CD16++ monocytes are able to produce high 
levels of IL-6, CCL2 chemokine and matrix metallopro-
teinase-9.39 Thus, their increased number and accumu-
lation onto endothelium may result in the recruitment 
of monocytes and T cell subsets at sites of inflammation 
in  response to  CCL2 and IL-6-induced cell activation 
and/or differentiation, and MMP-9-mediated vascular and 
tissue injury.39 
It  should be also underlined that  TNF-α may exert 
procoagulant activity and its expression by non-classical 
monocytes may lead to enhanced thrombin formation. 
It has been shown that TNF-α may downregulate throm-
bomodulin, a cofactor in protein C activation.40 More-
over, a  study performed in  healthy volunteers showed 
that TNF-α is able to induce a rapid inhibition of fibri-
nolysis mediated by a delayed increase in plasminogen 
activator inhibitor-1.41 It may be speculated that in VTE 
patients non-classical monocytes may play a role in im-
munothrombosis. In the mouse model of flow restriction-
induced DVT, it has been shown that the rapid accumu-
lation of neutrophils and monocytes is observed within 
a forming thrombus and innate immune cells initiate lo-
cal fibrin formation predominantly through the delivery 
of TF.17 Further studies are needed to elucidate monocyte-
derived mediators involved in VTE and the consequences 
of elevated non-classical monocytes.
In  the  current study we  also found the  associations 
between non-classical monocytes and age. It has been 
shown earlier that aging is associated with significant 
changes in monocyte subsets, which may have implica-
tions for the development of age-related diseases.
Fig. 2. The absolute number of non-classical CD14+CD16++ monocytes 
in venous thromboembolic patients (VTE) who experienced a last  
VTE event <12 and >12 months
This effect was not associated with unprovoked or provoked VTE.
VTE >12VTE <12
p = 0.01
Fig. 3. Non-classical CD14+CD16++ monocyte counts in patients with 
unprovoked and provoked venous thromboembolism (VTE)
p = 0.06
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In a cross-sectional study involving 91 healthy individu-
als, age was associated with an increased proportion of in-
termediate and non-classical monocytes.42 Most recently, 
it has been shown by Puchta et al. that intermediate human 
and mice monocytes produced more of the inflammatory 
cytokines IL-6 and TNF-α with age, both in the steady state 
and when stimulated with bacterial products.43
Moreover, we found that non-classical monocytes corre-
lated positively with BMI and glucose, which is in line with 
the previous findings.44,45 It has been shown that the pro-
portion of  intermediate and non-classical monocyte 
positively correlated with BMI and fasting glycemia 
in obese and type 2 diabetic patients.44 Moreover, it has 
been shown that CD16 positive monocyte subsets were 
reduced by drastic fat mass loss. This feature suggests 
that increased glycemia could be a parameter regulating 
intermediate and non-classical monocytes numbers.44 Fur-
thermore, the I LIKE HOMe study reveals a significant 
association between counts of non-classical monocytes 
but not of total monocytes or classical monocytes, and 
both obesity as well as subclinical atherosclerosis in a large 
cohort in low-risk individuals.45
Of note, we observed that the elevated number of non-
classical monocytes is decreased after 12 months of the VTE 
event, when the inflammatory process is resolved. This 
suggests the involvement of this subset in the acute throm-
bosis and the subsequent thrombus resolution.
We also showed a positive correlation of non-classical 
monocytes with elevated hsCRP level. 
Data on  the  relationship between monocyte subsets 
and inflammatory markers yielded inconsistent findings. 
In patients with unstable angina, CD16-positive monocytes 
were associated with hsCRP levels, but no such association 
was found in stable angina.22,23 Similar to our observations, 
an association of CRP levels and non-classical monocyte 
counts has been found in patients with rheumatoid arthri-
tis and type 1 diabetes mellitus.46,47 It should also be noted 
that specific single nucleotide polymorphisms in the CRP 
gene and other inflammatory and coagulation biomarkers 
are strongly associated with their plasma concentrations 
and may regulate the inflammatory processes.48
The present findings increase our knowledge on the role 
of  immune responses in  the  pathophysiology of  VTE 
by providing a new, monocyte-associated aspect of im-
munothrombosis, which suggests the involvement of non-
classical and intermediate monocytes in the early phase 
following an acute VTE episode. 
Several study limitations should be acknowledged. 
The number of patients with VTE and healthy controls was 
limited; however, the study was sufficiently powered. Nev-
ertheless, the subgroup analysis should be interpreted with 
caution. A well-matched control group is recommended 
to be used for future study on this topic. Furthermore, 
we determined each variable at a single time point. Our 
findings cannot be easily extrapolated to the elderly or pa-
tients with severe comorbidities, in particular cancer, who 
were excluded from our study. Associations reported here 
do not necessarily mean the cause-effect relationship and 
should be regarded as the hypothesis-generating investi-
gation, which can, however, have important implications. 
Moreover, observation at different time intervals after VTE 
event would introduce additional information on the pres-
ence and proportion of each subpopulation of monocytes. 
Finally, a long-term follow-up study is needed to assess 
a potential prognostic role of the current findings and 
investigate whether and when the intermediate and non-
classical monocyte subset populations can normalize.
To our knowledge, this is the first study which shows 
increased counts of non-classical and intermediate mono-
cyte subsets in patients following VTE, suggesting a new 
role of the immune system in this disease. Monocyte-re-
lated immunothrombotic mechanisms of VTE, that are 
more pronounced within the first months since the event, 
in particular that of unprovoked nature, provide new in-
sights into the pathophysiology of this common disease.
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